Experience

Davis Polk advised Hangzhou Tigermed Consulting Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in…

Davis Polk advised the sole placing agent for the placement of 56,200,000 new shares and 36,800,000 existing shares in Innovent Biologics, Inc., for an aggregate consideration of…

Davis Polk advised the initial purchasers in connection with a $300 million Regulation S offering by CIFI Holdings (Group) Co. Ltd. of its 5.950% senior notes due 2025. Established in 2000…

Davis Polk advised the initial purchasers in a Regulation S offering by Trip.com Group Limited of $500 million aggregate principal amount of 1.500% exchangeable senior notes due 2027…

Davis Polk advised the initial purchasers in connection with the Regulation S offering of $250 million principal amount of 9.000% senior notes due 2021 by RongXingDa Development (BVI)…

Davis Polk advised the initial purchasers in connection with a $170 million Regulation S offering by Golden Wheel Tiandi Holdings Limited of its 14.250% senior notes due 2023. Golden Wheel…

Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock Exchange and an international offering and listing in reliance on Rule…

Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering…

Davis Polk advised the joint lead managers in connection with the debut offering of $300 million 2.125% bonds due 2025 issued by New Oriental Education & Technology Group Inc. New…

Davis Polk advised Genetron Holdings Limited on its SEC-registered initial public offering of 16,000,000 American Depositary Shares. Each ADS represents five ordinary shares. Genetron has…